Cochrane · systematic review · CD009839
Mesalamine (5‐ASA) for the prevention of recurrent diverticulitis
Carter, F, Alsayb, M, Marshall, JK, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
ColorectalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
5‐ASA compared with control (all trials) for prevention of recurrent diverticulitis
Population: patients with the need for management of diverticulitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence of diverticulitis 5‐ASA vs control (all trials) | RR 0.69 [0.43, 1.09] | 7 studies · 1805 participants | Very low Downgraded: risk of bias |
Number of participants with adverse events (epigastric pain, nausea, diarrhoea) 5‐ASA vs control (all trials) | RR 0.98 [0.91, 1.06] | 5 studies · 1421 participants | Moderate Downgraded: risk of bias |